<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112381</url>
  </required_header>
  <id_info>
    <org_study_id>ET005</org_study_id>
    <nct_id>NCT04112381</nct_id>
  </id_info>
  <brief_title>Bilateral Treatment of Medication Refractory Essential Tremor</brief_title>
  <official_title>A Pivotal Clinical Trial to Evaluate the Safety and Efficacy of Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy&#xD;
      procedure can be performed on both sides of the brain safely and effectively to reduce&#xD;
      bilateral tremor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device and procedure related adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>rate of adverse events following the Exablate secondary procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Exablate Secondary Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalamotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exablate Model 4000 Type 1.0/1.1</intervention_name>
    <description>Exablate thalamotomy of non tremor dominant side of the brain</description>
    <arm_group_label>Exablate Secondary Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women age 22 years or older&#xD;
&#xD;
          2. Diagnosis of medication-refractory Essential Tremor&#xD;
&#xD;
          3. Has previously underwent an Exablate index procedure in a clinical trial or in a&#xD;
             commercial setting at least 9 months prior to enrolling in this trial&#xD;
&#xD;
          4. Able to communicate sensations during the Exablate thalamotomy procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has experienced any non-transient neurological event or worsening following the&#xD;
             Exablate index procedure&#xD;
&#xD;
          2. Presence of unknown or MR unsafe devices anywhere in the body&#xD;
&#xD;
          3. Non-transient hemiparesis as determined by physical examination&#xD;
&#xD;
          4. Clinically significant abnormal speech function as determined by a speech pathologist&#xD;
&#xD;
          5. Pregnant or breastfeeding&#xD;
&#xD;
          6. Unstable cardiac status&#xD;
&#xD;
          7. Behavior(s) consistent with ethanol or substance abuse&#xD;
&#xD;
          8. History of bleeding disorder&#xD;
&#xD;
          9. Has received anticoagulants within one month of Exablate procedure&#xD;
&#xD;
         10. Cerebrovascular disease&#xD;
&#xD;
         11. Intracranial tumor&#xD;
&#xD;
         12. Active or suspected acute or chronic uncontrolled infection&#xD;
&#xD;
         13. Has previously had deep brain stimulation or a prior stereotactic ablation of the&#xD;
             basal ganglia or thalamus&#xD;
&#xD;
         14. Implanted objects in the skull or the brain&#xD;
&#xD;
         15. Currently in a clinical trial involving an investigational product or non-approved use&#xD;
             of a drug or device or in any other type of medical research&#xD;
&#xD;
         16. Unable to communicate with the investigator and staff&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

